Published in J Clin Pharm Ther on February 01, 2011
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist (2013) 1.70
Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ (2013) 0.96
Efficient allocation of novel agents in multiple myeloma: a work in progress. Oncologist (2013) 0.80
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5. Oncol Ther (2017) 0.75
The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 15.12
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
Viridans streptococcal bacteraemia in patients with neutropenia. Lancet (1995) 2.46
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Actin-based movement of Listeria monocytogenes: actin assembly results from the local maintenance of uncapped filament barbed ends at the bacterium surface. J Cell Biol (1995) 2.27
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 2.07
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost (2005) 1.80
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia (2010) 1.59
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
P53 deletion is not a frequent event in multiple myeloma. Br J Haematol (1999) 1.57
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res (1999) 1.55
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Prophage lambda induction of Escherichia coli K12 envA uvrB: a highly sensitive test for potential carcinogens. Proc Natl Acad Sci U S A (1976) 1.54
Autosomal dominant spondyloarthropathy. N Engl J Med (1989) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res (1999) 1.53
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. Bone Marrow Transplant (1995) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia (2011) 1.43
[Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical treatment and costs]. Rev Mal Respir (1996) 1.41
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem (1975) 1.39
Interferon alpha-2b therapy in refractory adult chronic thrombocytopenic purpura. Br J Haematol (1991) 1.39
[Invasive aspergillosis in intensive care]. Ann Fr Anesth Reanim (1995) 1.39
Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood (1995) 1.39
Bone densitometry in patients with multiple myeloma. Am J Med (1992) 1.38
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
A micro tissue culture test for the titration and neutralization of rubella virus. Can J Microbiol (1969) 1.33
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Simian virus 40 late promoter region able to initiate simian virus 40 early gene transcription in the absence of the simian virus 40 origin sequence. J Virol (1984) 1.29
An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci U S A (1994) 1.23
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res (1999) 1.23
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol (1999) 1.19
Toxoplasmosis in kidney transplant recipients: report of six cases and review. Clin Infect Dis (1997) 1.19
Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg (1998) 1.18
Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens (2003) 1.18
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis (1997) 1.17
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood (1999) 1.16
HLA-G: a shield against inflammatory aggression. Trends Immunol (2001) 1.15
Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis (2001) 1.12
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health (2006) 1.11
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Communicating with cancer patients in Saudi Arabia. Ann N Y Acad Sci (1997) 1.10
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia (1997) 1.09
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res (1998) 1.09
Study of the B cell memory compartment in common variable immunodeficiency. Eur J Immunol (2000) 1.09
Pitfalls in the diagnosis of leg pain. Can Med Assoc J (1979) 1.08
Significant impact of survivin on myeloma cell growth. Leukemia (2007) 1.08
Interleukin-6 serum levels in patients with multiple myeloma. Br J Haematol (1994) 1.08
Blindness, low vision, and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol (2004) 1.07
The genetic structure of 3'untranslated region of the HLA-G gene: polymorphisms and haplotypes. Genes Immun (2009) 1.07
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant (2001) 1.06
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood (2001) 1.06
A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem (2000) 1.05
Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol (1996) 1.05
Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys (2001) 1.05
18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol (2010) 1.03
Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum (1993) 1.02
Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther (2008) 1.02
[POEMS syndrome]. Rev Med Interne (1997) 1.02
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma (2011) 1.02
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer (1999) 1.01
The association of chronic lymphocytic leukaemia and multiple myeloma: a study of eleven patients. Br J Haematol (1985) 1.00
Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. Cell Mol Life Sci (2001) 1.00
Primary plasma cell leukaemia: a report of 18 cases. Leuk Res (2001) 1.00
Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab (2000) 1.00
Interleukin 2-induced proliferation of leukemic human B cells. J Exp Med (1985) 1.00
Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases. Cancer (1993) 0.99